1003 related articles for article (PubMed ID: 32036071)
1. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
Gao S; Li N; Gao S; Xue Q; Ying J; Wang S; Tao X; Zhao J; Mao Y; Wang B; Shao K; Lei W; Wang D; Lv F; Zhao L; Zhang F; Zhao Z; Su K; Tan F; Gao Y; Sun N; Wu D; Yu Y; Ling Y; Wang Z; Duan C; Tang W; Zhang L; He S; Wu N; Wang J; He J
J Thorac Oncol; 2020 May; 15(5):816-826. PubMed ID: 32036071
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
3. Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC.
Zhang F; Guo W; Zhou B; Wang S; Li N; Qiu B; Lv F; Zhao L; Li J; Shao K; Xue Q; Gao S; He J
J Thorac Oncol; 2022 Jul; 17(7):909-920. PubMed ID: 35550174
[TBL] [Abstract][Full Text] [Related]
4. The efficiency of
Tao X; Li N; Wu N; He J; Ying J; Gao S; Wang S; Wang J; Wang Z; Ling Y; Tang W; Zhang Z
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1209-1219. PubMed ID: 32043180
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
[TBL] [Abstract][Full Text] [Related]
7. Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.
Shi L; Meng Q; Tong L; Li H; Dong Y; Su C; Liu Z
Front Oncol; 2022; 12():956755. PubMed ID: 36313678
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.
Zhao J; Zhao L; Guo W; Wang S; Tao X; Li L; Mao Y; Tan F; Gao Y; Wu N; Ying J; Xue Q; Li N; Gao S; He J
J Thorac Oncol; 2023 Jun; 18(6):780-791. PubMed ID: 36870519
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Xu H; Wang W; Yin J; Song C; Li L; Sun Z
Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
12. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
13. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer.
Zhang X; Shao M; Yao J; Zhao L; Li L; Chen M; Zhang Y; Liu H; Chen Z; Li B; Wu Z; Fan J; Qiu F
Future Oncol; 2024 Jan; 20(3):121-129. PubMed ID: 38353107
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
Hou H; Wang Y; Sun D; Zhu J; Jiang M; Zhang X; Zhou N; Zhang C; Li T; Zhang X
Invest New Drugs; 2023 Feb; 41(1):86-92. PubMed ID: 36508040
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial.
Guo H; Ding P; Sun C; Yang P; Tian Y; Liu Y; Lowe S; Bentley R; Li Y; Zhang Z; Wang D; Li Y; Zhao Q
Front Oncol; 2022; 12():927781. PubMed ID: 36091139
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
Eichhorn F; Klotz LV; Kriegsmann M; Bischoff H; Schneider MA; Muley T; Kriegsmann K; Haberkorn U; Heussel CP; Savai R; Zoernig I; Jaeger D; Thomas M; Hoffmann H; Winter H; Eichhorn ME
Lung Cancer; 2021 Mar; 153():150-157. PubMed ID: 33529989
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
[TBL] [Abstract][Full Text] [Related]
20. A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Zhou L; Xiong Y; Wang Y; Meng Y; Zhang W; Shen M; Zhang X; Li S; Ren B; Li R; Han Y; Zhang J; Cao S; Du W; Sun Q; Wei F; An X; Yang L; Zhang Y; Ma W; Xu W; Zhang Y; Jiang J; Xu X; Xia J; Liu L; Ren X
Clin Lung Cancer; 2022 Dec; 23(8):709-719. PubMed ID: 35995696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
